View all SABCS CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recap
for Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future focuses on a series of video interviews with leading experts in the treatment of triple-negative breast cancer that are featured in an online CME activity currently available at

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Astellas Pharma, and Medivation, Inc.

Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future

Release Date: February 29, 2016
Expiration Date: February 28, 2017
Media: Internet - based

Activity Overview

This activity focuses on triple-negative breast cancer, and features a series of short video interviews with leading experts in the treatment of breast cancer. The content and interviews are based on presentations given at Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future, a CME-certified, ancillary satellite symposium held in San Antonio, Texas.

CME Activity Table of Contents

  • Advancing Treatment of TNBC in Real-World Clinical Scenarios
  • PARP Inhibitors, PI3K/AKT Inhibitors, and Other Novel Approaches for Basal-Like TNBC
  • Androgen Receptor-Targeted Agents and Other Strategies for Luminal/Apocrine Subtypes
  • Novel Therapeutic Hypotheses for TNBC
  • Summary and Take Home Points

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, nurses, and other healthcare professionals who manage patients with breast cancer.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Discuss the biology of triple-negative breast cancer (TNBC) in the context of standard approaches and unmet clinical needs in the field
  • Explain novel mechanistic approaches under investigation for the treatment of patients with TNBC
  • Detail current and emerging clinical trial information concerning the use of investigational therapeutic approaches to care for patients with TNBC
  • Evaluate recent clinical trial findings and place them in the context of unmet clinical needs, evolving treatment paradigms in the field, and the need for participation in clinical trials evaluating novel TNBC management strategies

Faculty, Staff, and Planners' Disclosures


Jenny C. Chang, MD
Emily Herrmann Chair in Cancer Research
Director, Houston Methodist Cancer Center
Professor of Cancer, Weill Cornell Medical College
Houston, TX

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women’s Cancer Care
Robert H. Lurie Comprehensive Cancer Center of
Feinberg School of Medicine
Northwestern University
Chicago, IL

Joyce A. O'Shaughnessy, MD
Chair, Breast Cancer Research
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Tiffany A. Traina, MD
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY

The following individuals have no relevant financial relationships with commercial interests:

William J. Gradishar, MD, FASCO, FACP; Jenny C. Chang, MD

The following individuals have relevant financial relationships with commercial interests to disclose:

Joyce A. O'Shaughnessy, MD – Advisory Board/ Consultant: Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Johnson & Johnson, Lilly, Medfusion, Merrimack Pharmaceuticals, Millennium: The Takeda Oncology Company, Novartis, Pfizer, sanofi-aventis; Hope S. Rugo, MD – Speakers Bureau: Genomic Health; Grant/Research Support: Amgen, Eisai, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Merck & Co., Novartis, OBI Pharma, Pfizer, Plexxikon, Roche Pharmaceuticals; Tiffany A. Traina, MD – Consultant: Genentech/Roche, Eisai, Halozyme Therapeutics, Mundipharma, Medivation, Pfizer, AstraZeneca, Bayer, Immunomedics; Research: Medivation, Eisai, Pfizer, Novartis, Myriad Genetics

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By